Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Chung, Susannah (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000
Reexamination Certificate
active
07897599
ABSTRACT:
The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
REFERENCES:
patent: 3546219 (1970-12-01), Long et al.
patent: 3626008 (1971-12-01), Biland et al.
patent: 4029671 (1977-06-01), Friedman et al.
patent: 4761424 (1988-08-01), Carethers et al.
patent: 6143931 (2000-11-01), Baldino et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6452050 (2002-09-01), Baldino et al.
patent: 6525046 (2003-02-01), Cirillo et al.
patent: 6562558 (2003-05-01), Bealev et al.
patent: 6583282 (2003-06-01), Zhang et al.
patent: 6734301 (2004-05-01), Ennis et al.
patent: 6794380 (2004-09-01), Brown
patent: 6797267 (2004-09-01), Horwitz
patent: 2003/0008868 (2003-01-01), Francesco Cirillo et al.
patent: 2003/0060455 (2003-03-01), Moss et al.
patent: 2003/0068340 (2003-04-01), Cappola et al.
patent: 2003/0125354 (2003-07-01), Hao et al.
patent: 2003/0130309 (2003-07-01), Moss et al.
patent: 2003/0162968 (2003-08-01), Cirillo et al.
patent: 2003/0225089 (2003-12-01), Jung et al.
patent: 2003/0236193 (2003-12-01), Oliner et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0044020 (2004-03-01), Meade et al.
patent: 2004/0048797 (2004-03-01), Miller et al.
patent: 2004/0110755 (2004-06-01), Simianer et al.
patent: 2004/0166111 (2004-08-01), Kaymakcalan et al.
patent: 2004/0192653 (2004-09-01), Munson et al.
patent: 2004/0192748 (2004-09-01), Barbosa, Jr. et al.
patent: 2004/0198697 (2004-10-01), Cohen et al.
patent: 2005/0107399 (2005-05-01), Boman et al.
patent: 2005/0176687 (2005-08-01), Moussy et al.
patent: 2010/0093734 (2010-04-01), Boman et al.
patent: 190457 (1986-08-01), None
patent: 00490263 (1992-06-01), None
patent: 514264 (1992-11-01), None
patent: 661260 (1995-07-01), None
patent: 747347 (1996-12-01), None
patent: 1022027 (2000-07-01), None
patent: 2834288 (2003-07-01), None
patent: 05201980 (1993-08-01), None
patent: 07224041 (1995-08-01), None
patent: 2001031636 (2001-02-01), None
patent: 2003335733 (2003-11-01), None
patent: WO 92/06948 (1992-04-01), None
patent: WO 98/09946 (1998-03-01), None
patent: WO 98/46551 (1998-10-01), None
patent: WO 98/46559 (1998-10-01), None
patent: WO 99/23091 (1999-05-01), None
patent: WO 99/32110 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 99/51224 (1999-10-01), None
patent: WO 99/55696 (1999-11-01), None
patent: WO 99/64044 (1999-12-01), None
patent: WO 00/16769 (2000-03-01), None
patent: WO 00/18725 (2000-04-01), None
patent: WO 00/18738 (2000-04-01), None
patent: WO 00/43384 (2000-07-01), None
patent: WO 00/50425 (2000-08-01), None
patent: WO 00/55151 (2000-09-01), None
patent: WO 01/01986 (2001-01-01), None
patent: WO 01/10821 (2001-02-01), None
patent: WO 01/12187 (2001-02-01), None
patent: WO 01/12189 (2001-02-01), None
patent: WO 01/36403 (2001-05-01), None
patent: WO 01/47913 (2001-07-01), None
patent: WO 01/47916 (2001-07-01), None
patent: WO 01/55144 (2001-08-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 02/08225 (2002-01-01), None
patent: WO 02/32862 (2002-04-01), None
patent: WO 02/42248 (2002-05-01), None
patent: WO 02/42292 (2002-05-01), None
patent: WO 02/006644 (2002-08-01), None
patent: WO 02/072571 (2002-09-01), None
patent: WO 02/083628 (2002-10-01), None
patent: WO 02/085859 (2002-10-01), None
patent: WO 02/092576 (2002-11-01), None
patent: WO 02/096876 (2002-12-01), None
patent: WO 02/098869 (2002-12-01), None
patent: WO 03/000680 (2003-01-01), None
patent: WO 03/005999 (2003-01-01), None
patent: WO 03/010159 (2003-02-01), None
patent: WO 03/022273 (2003-03-01), None
patent: WO 03/049742 (2003-06-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/068223 (2003-08-01), None
patent: WO 03/072569 (2003-09-01), None
patent: WO 03/084539 (2003-10-01), None
patent: WO 2004/004725 (2004-01-01), None
patent: WO 2004/013127 (2004-02-01), None
patent: WO 2004/022041 (2004-03-01), None
patent: WO 2004/024727 (2004-03-01), None
patent: WO 2004/045607 (2004-06-01), None
patent: WO 2004/058724 (2004-07-01), None
patent: WO 2004/083193 (2004-09-01), None
Abjil, Atherosclerose en ontsteking: de betekenis van C-reactieve proteine. Ned Tijdschr Geneeskd, 2003,147(1),15-20.
Ablamunits, et. aI., Islet T Cells Secreting IFN-γ in NOD Mouse Diabetes: Arrest by p277 Peptide Treatment: J. Autoimmun., 1988, 11, 73-81.
Abu-Amer, et. aI., Tumor Necrosis Factor Receptors Types 1 and 2 Differentially Regulate Osteoclastogenesis: J. BioI. Chem., 2000, 275(35), 27307-10.
Akaike, et. aI., Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO: Proc. Soc: Exp. BioI. Med., 1998,217,64-73.
Alexander, et. al., Mechanisms of innate resistance toToxoplasma gondiiinfection: Philos. Trans. R. Soc. Lond. B. BioI. Sci., 1997,352, 1355-1359.
Aliev et aI., Synthesis and structure of 5-p-ethoxyphenyl-3-methoxycarbonyl-1-p-tolyl-4-ptolyloxamoylpyrazole. Russian Chemical Bulletin (Translation of Izvestiya Akademil Nauk, Seriya Khimicheskaya), 48(3): 604-607, 1999.
Bacqui, et. aI., “Enhanced Interleukin-1J3, Interleukin-6 and Tumor Necrosis Factor-a Production By LPS Stimulated Human Monocytes Isolated From HIV + Patients,” Immunopharmacol. Immunotoxicol, 2000,22(3),401-421.
Baronzio, et. aI., Proinflammatory and regulatory cytokine levels in AIDS cachexia: In Vivo, 1999, 13(6),499-502.
Barry, et. al., A Molecular Rearrangement During the Reduction of Thionaphthenopyrazole Dioxides: J. Chem. Soc., 1956,4974-4978.
Bartens and Pusch, Oxindigo, Dibenzo-4,5,4′,5′ and dibenzo-6,7,6′,7,-oxindigo. Ann. 442:254-305, 1925. (English Abstract of a Section of Reference C46—Fries below).
Beisel. “Herman Award Lecture, 1995: infection-induced malnutrition-from cholera to cytokines,” Am. J. Clin. Nutr., 1995.62,813-819.
Ben-Bassat, Biological activity of tyrosine kinase inhibitors: Novel agents for psoriasis therapy,n Current Opinion in Investigational Drugs, 2001,2(11), 1539-1545.
Bodor, “Novel Approaches in Prodrug Design,” Drugs of the Future, 1981,6,165-182.
Bonay. “Characterization of proliferative responses and cytokine mRNA profiles induced byVespulavenom in patients with severe reactions to wasp stings,” Clin. Exp. Immunol., 1997, 109,342-350.
Borjesson, et. aI., TNF-a stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats, Amer. J. Physiol., 2000, 278, L-3-L12.
Bozkurt, “Results of Targeted Anti-Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure,” Circulation, 2001, Feb. 27, 103(8) 1044-1047.
Branger, et. al.. “Anti-Inflammatory Effects of a p38 Mitogen-Activatcd Protein Kinase Inhibitor During Human Endotoxemia,” J. Immunol.. 2002, 168(8) 4070-4.
Bresnihan. et. aI., Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist, Arthritis. Rheum., 1998. 41 :2196-2204.
Bruserud, “Effects of Endogenous Interleukin 1 on Blast Cells Derived From Acute Myelognoeus Leukemia Patients,” Leukemia Res., 1996,20,65-73.
Burke, et. al., “Early Development of Acute Myelogenous Leukemia Following Kidney Transplantation: Possible Role of Multiple Serum Cytokines,” Leuk. Lymphoma., 1995, 19, 173-180.
Chen et al., Rapid synthesis of a-ketoamidcs using microwave irradiation-simultaneous cooling method. Tetrahedron Lett., 44:8873-8876. 2003.
Chevalier, “Upregulation of enzymatic activity by interleukin-1 in osteoarthritis,” Biomed. Pharmacother., 1997, 51, 58-62.
Childs, “Efficacy of Etanercept for Wear Debris -Induced Osteolysis,” J. Bone Miner. Res., 2001, 16, 338-347.
Chisari, et. aI., “Hepatitis B virus immunology,” Sprinter Semin. Immunopathol., 1995, 17,261-281.
Clarmunt, et. al., “3(5)-(1-Adamantyl)pyr
Boman Erik
Ceide Susana Conde
Dahl Russell
Delaet Nancy G. J.
Ernst Justin
Chung Susannah
iTherX Pharmaceuticals Inc.
Jones Day
LandOfFree
Cytokine inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696666